Clinical study of 20 cases of refractory Mycobacterium avium complex pulmonary disease treated with amikacin liposomal inhalation suspension

被引：0
|
作者：
Kaneko, Taichi [1 ]
Hagiwara, Eri [1 ]
Okuda, Ryo [1 ]
Ogura, Takashi [1 ]
机构：
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
来源：
RESPIROLOGY | 2024年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO13-003
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [1] Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory Mycobacterium avium Complex Pulmonary Disease
    Kurahara, Yu
    Yoshida, Shiomi
    Osugi, Asami
    Tanaka, Yuya
    Kobayashi, Takehiko
    Mitsuhashi, Toshiharu
    Kawasaki, Yohei
    Mitarai, Satoshi
    Tsuyuguchi, Kazunari
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [2] Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Sae Rom
    Jhun, Byung Woo
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (02) : 202 - 205
  • [3] Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease
    Yanagihara, Toyoshi
    Ogata, Hiroaki
    Mori, Asami
    Kadowaki, Masako
    Moriuchi, Yuki
    Ishimatsu, Akiko
    Otsuka, Junji
    Taguchi, Kazuhito
    Moriwaki, Atushi
    Yoshida, Makoto
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [4] Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
    Urabe, Naohisa
    Sakamoto, Susumu
    Tokita, Nozomi
    Yoshida, Hiromichi
    Usui, Yusuke
    Shimizu, Hiroshige
    Sekiya, Muneyuki
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Isobe, Kazutoshi
    Kishi, Kazuma
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [5] Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease
    Marras, Theodore K.
    Hassan, Mariam
    Mange, Kevin C.
    Ciesielska, Monika
    Murthy, Shilpa Dhar
    Jumadilova, Zhanna
    Chatterjee, Anjan
    ERJ OPEN RESEARCH, 2022, 8 (03)
  • [6] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    Clinical Drug Investigation, 2021, 41 : 405 - 412
  • [7] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Hoy, Sheridan M.
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 405 - 412
  • [8] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Matt Shirley
    Drugs, 2019, 79 : 555 - 562
  • [9] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Shirley, Matt
    DRUGS, 2019, 79 (05) : 555 - 562
  • [10] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
    Griffith, David E.
    Eagle, Gina
    Thomson, Rachel
    Aksamit, Timothy R.
    Hasegawa, Naoki
    Morimoto, Kozo
    Addrizzo-Harris, Doreen J.
    O'Donnell, Anne E.
    Marras, Theodore K.
    Flume, Patrick A.
    Loebinger, Michael R.
    Morgan, Lucy
    Codecasa, Luigi R.
    Hill, Adam T.
    Ruoss, Stephen J.
    Yim, Jae-Joon
    Ringshausen, Felix C.
    Field, Stephen K.
    Philley, Julie V.
    Wallace, Richard J., Jr.
    van Ingen, Jakko
    Coulter, Chris
    Nezamis, James
    Winthrop, Kevin L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
12345